Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-Hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, Koga H, Torimura T. Kuromatsu R, et al. Among authors: niizeki t. Cancers (Basel). 2022 May 4;14(9):2295. doi: 10.3390/cancers14092295. Cancers (Basel). 2022. PMID: 35565424 Free PMC article.
Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M. Nagaoka S, et al. Among authors: niizeki t. Liver Int. 2007 Oct;27(8):1091-7. doi: 10.1111/j.1478-3231.2007.01550.x. Liver Int. 2007. PMID: 17845537
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Niizeki T, et al. J Gastroenterol. 2012 Jun;47(6):686-95. doi: 10.1007/s00535-012-0555-6. Epub 2012 Mar 1. J Gastroenterol. 2012. PMID: 22382631 Clinical Trial.
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M. Nakano M, et al. Among authors: niizeki t. Oncology. 2013;84(2):108-14. doi: 10.1159/000342650. Epub 2012 Nov 9. Oncology. 2013. PMID: 23147476
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: niizeki t. Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16. Cancer Med. 2015. PMID: 26471348 Free PMC article.
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S, Kuromatsu R, Matsugaki S, Kurogi J, Kajiwara M, Koga H, Torimura T. Nagamatsu H, et al. Among authors: niizeki t. Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50. doi: 10.1007/s00280-015-2892-7. Epub 2016 Jan 11. Cancer Chemother Pharmacol. 2016. PMID: 26754678 Clinical Trial.
164 results